Consistent with the findings reported in previous studies (Lian et al., 2018), our results showed that higher ANLN expression levels are associated with worse clinical outcomes and a shorter survival times of patients with HCC, thereby highlighting the potential use of ANLN as a prognostic biomarker. The gene discussed is ANLN; the disease is hepatocellular carcinoma.